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KRAS gene amplification and overexpression but not mutation
associates with aggressive and metastatic endometrial cancer
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BACKGROUND: Three quarter of endometrial carcinomas are treated at early stage. Still, 15 to 20% of these patients experience
recurrence, with little effect from systemic therapies. Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue (KRAS)
mutations have been reported to have an important role in tumorigenesis for human cancers, but there is limited knowledge
regarding clinical relevance of KRAS status in endometrial carcinomas.
METHODS: We have performed a comprehensive and integrated characterisation of genome-wide expression related to KRAS
mutations and copy-number alterations in primary- and metastatic endometrial carcinoma lesions in relation to clinical and
histopathological data. A primary investigation set and clinical validation set was applied, consisting of 414 primary tumours and
61 metastatic lesions totally.
RESULTS: Amplification and gain of KRAS present in 3% of the primary lesions and 18% of metastatic lesions correlated significantly with
poor outcome, high International Federation of Gynaecology and Obstetrics stage, non-endometrioid subtype, high grade,
aneuploidy, receptor loss and high KRAS mRNA levels, also found to be associated with aggressive phenotype. In contrast, KRAS
mutations were present in 14.7% of primary lesions with no increase in metastatic lesions, and did not influence outcome, but was
significantly associated with endometrioid subtype, low grade and obesity.
CONCLUSION: These results support that KRAS amplification and KRAS mRNA expression, both increasing from primary to metastatic
lesions, are relevant for endometrial carcinoma disease progression.
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Endometrial cancer is the most common pelvic gynaecological
malignancy in industrialised countries. Although 75% are treated
at an early stage, 15 to 20% recur. There is a need for more
effective systemic therapies, as no new targeted therapies are yet
available in standard clinical care, and response to conventional
systemic therapy is limited (Dedes et al, 2011). Several prognostic
markers exist, and recent studies have indicated promising new
targets to develop novel strategies for systemic therapies in
endometrial cancer (Salvesen et al, 2009). Still, no markers are
available to predict response to such therapy.
Traditionally, endometrial cancer has been divided into two
subgroups, type I and type II carcinomas, to assess the risk of
recurrent disease. Type I endometrial carcinoma is associated with
good prognosis, low grade, endometrioid morphology and rarely
metastasise to regional and distant sites (Fujimoto et al, 2009). Type
II endometrial carcinoma is associated with poor prognosis, non-
endometrioid histology and high grade. Still, there is considerable
overlap, and as tool to predict prognosis this classification may be
improved, as 20% of type I cancers recur and 50% of type II cancers
do not. Although the molecular alterations reported for type I and
type II cancers are overlapping, type I cancers are significantly more
often Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogene
(KRAS) and PTEN mutated, microsatellite instable, diploid and
expressing oestrogen- and progesterone receptors (ER, PR) (Lax
et al, 1998). Type II cancers, in contrast are more often aneuploid
and with altered expression of p53, p16 and with hormone receptor
loss. These differences are of prognostic value; nevertheless, the
molecular characteristics distinguishing Type I and Type II cancers
have so far had limited impact for tailoring systemic therapies.
Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogenes
homologue is a small GTPase and a member of the RAS
superfamily of proteins linked to the carcinogenic process in
preclinical models. Knock-down of KRAS in pancreatic cancer cell
lines leads to decreased motility and proliferation and a decreased
expression of pERK1/2, SNAIL and Nf-kB, all factors related to
epithelial to mesenchymal transition (Rachagani et al, 2011).
In colorectal cancer, KRAS has been reported to induce VEGF and
inhibit apoptosis through Akt phosphorylation under hypoxic
conditions (Zeng et al, 2010).
Activating KRAS mutations have been detected in precursor
lesions for colorectal and endometrial cancers indicating that these
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are early events (Dobrzycka et al, 2009). Mutations have been
found to have a prognostic impact in lung-, pancreatic- and
colorectal cancers (Gautschi et al, 2007; Ling et al, 2012).
In endometrial cancer, findings have been inconsistent, with
reported different prognostic impact for different age groups (Ito
et al, 1996; Semczuk et al, 1998). Furthermore, KRAS mutations
have been found to predict lack of response to EGFR inhibition in
lung- and colorectal cancers (Cepero et al, 2010). In endometrial
cancer trials of EGFR inhibitors have been limited, although some
studies reported partial response (Oza et al, 2008; Dedes et al,
2011).
Other measures for KRAS alterations, although less studied than
mutations, have supported a relevance of KRAS status for clinical
phenotype in cancer (Wagner et al, 2011). In lung cancer patients
with KRAS amplification and KRAS mutations, the latter only
associated with poor survival, but with no independent prediction
of response to therapy (Sasaki et al, 2011). Lung cancers
with KRAS amplification have been reported to have increased
expression levels of p21 (CDK1), suggesting an impact on cell cycle
regulation (Wagner et al, 2009). In endometrial cancers, one
previous study demonstrated a poor prognostic impact of
amplifications of the 12p12.1 region harbouring KRAS (Salvesen
et al, 2009). On this background, we have investigated several
aspects of KRAS alterations including mutation, amplification and
mRNA levels in relation to transcriptional alterations and clinical
phenotype. To study this, we have applied a unique sample set of
freshly frozen primary- and metastatic endometrial carcinoma
lesions as primary investigation set for a global and comprehensive
characterisation of molecular changes, and an independent, large
and extensively annotated patient series for validation of findings.
In particular, we wanted to investigate which KRAS alterations in
endometrial carcinoma that link to aggressive disease.
MATERIALS AND METHODS
Patient series
From May 2001 through 2009, freshly frozen and formalin-fixed
paraffin-embedded (FFPE) tissues have been prospectively
collected from primary- and metastatic endometrial carcinoma
lesions from patients treated at the Department of Gynaecology
and Obstetrics, Haukeland University Hospital, Bergen, Norway,
after collection of informed consent. In total 461 patients where
included for the various analyses in this study. Formalin-fixed
paraffin-embedded tumour tissue from hysterectomy specimens
from 414 primary tumours and 61 metastatic lesions were
mounted in tissue micro arrays (TMA) for amplification studies
of KRAS using fluorescence in situ hybridisation (FISH). DNA and
RNA were extracted from freshly frozen tissue from 264 primary-
and 22 metastatic lesions. Two hundred fifteen of these primary
tumours and all metastases were included in the FISH series.
Extracted DNA was used for SNP array- (74 patients) and mutation
analyses (264 patients), RNA were applied for micro-array
analysis (122 patients) and 161 patients were used for the qPCR
validation series. Primary tumour tissue in TMAs were analysed by
immunohistochemistry for ER, PR and p53 protein expressions
(461, 461 and 390 patients, respectively). The research has been
approved by the Norwegian Data Inspectorate (961478-2),
Norwegian Social Sciences Data Services (15501) and the Local
ethical committee (REKIII nr. 052.01). Women gave informed
consent.
Clinico-pathological data including age at diagnosis, Interna-
tional Federation of Gynaecology and Obstetrics (FIGO) stage
according to the 2009 criteria (FIGO IFoGaO, 1989; Mikuta, 1993),
histological subtype and grade, treatment and follow-up informa-
tion were available for all cases and were investigated in relation to
KRAS alterations.
Follow-up data regarding recurrence and survival were collected
from patient records and correspondence with physicians
responsible for outpatient care. Data were crosschecked with data
registered at the Norwegian Cancer Registry and Register for
Causes of deaths, Statistics, Norway. Date of last follow-up was
April 1st 2010. The median follow-up for survivors was 39 months
(range 2–90), 48 (12%) patients died because of endometrial
cancer during follow-up.
The therapy consisted of hysterectomy and bilateral salpingo-
oophorectomy unless surgery was contraindicated owing to
co-morbidity. Pelvic lymphadenectomy as part of surgical staging
was conducted after an overall assessment of the patients’
condition by the responsible surgeon as previously reported
(Trovik et al, 2011). Adjuvant therapy was recommended for
patients with FIGO stage XII and high-risk FIGO stage I patients,
defined as non-endometrioid tumours or deeply infiltrating
endometrioid grade 3 tumours. Of the 461 patients included in
our analysis 122 (26.4%) patients were given adjuvant treatment.
External radiation was given to 58 (12.6%), internal radiation to
2 (0.4%), chemotherapy to 54 (11.7%), anti-hormonal treatment to
5 (1.1%) and chemotherapy combined with radiation to 3 (0.7%)
patients.
Tissue micro-array construction
Haematoxylin and eosin-stained slides from individual tumour
specimens were evaluated to identify the area of highest tumour
purity. Tissue cylinders of diameter 0.6mm were punched out
from the selected areas for each corresponding paraffin block and
mounted into a recipient block using a custom-made precision
instrument (Beecher Instruments, Silver Spring, MD, USA). This
method has been described and its usefulness validated in several
earlier publications (Kononen et al, 1998; Engelsen et al, 2006).
The recipient blocks were treated at 40 1C for 20min and stored at
4 1C before 5 mm microtome sectioning for FISH analyses.
Representative tumour tissue was available in TMAs for FISH
from 414 hysterectomy specimens and from 61 corresponding
metastatic lesions of these patients.
Immunohistochemistry
Tissue micro array sections were dewaxed in xylene and
rehydrated in ethanol before microwave antibody retrieval.
The sections were incubated for 60min with p53 antibody
(Dako M7001, Copenhagen, Denmark), diluted 1:1000 and for
ER and PR as previously reported (Engelsen et al, 2008; Krakstad
et al, 2012). The staining was recorded as previously described
(Salvesen et al, 2000). In short, a semi-quantitative and subjective
grading system was used, and a staining index was calculated as a
product of staining intensity (0–3) and area of positive tumour
cells (1p10%, 2¼ 10–50% and 3X50%).
Copy-number assessment
For FISH analysis, TMA sections were incubated at 56 1C overnight
and treated according to the Paraffin Pre-treatment Protocol (Abbot
molecular, Wiesbaden, Germany). Hybridisation was performed
according to protocol from Abbot molecular. Briefly the sections
were dewaxed in xylene, dehydrated in 100% ethanol, air-dried and
treated with proteases for 12min, denatured and hybridised overnight
at 37 1C with KRAS/centromere enumeration probe (KRAS/CEP12q;
Abbot Molecular). Slides were washed with post hybridisation buffer
at 72 1C, counterstained with 40,60-diamidino-2-phenylindole (DAPI),
mounted, and stored in the dark before signal enumeration. For
FISH analysis, the slides were examined by Zeiss fluorescence micro-
scope (Go¨ttingen, Germany) equipped with a  63 oil immersion
objective. Each slide was scanned at low power with a DAPI filter
to recognise the TMA map. Areas of optimal tissue digestion and
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no overlapping nuclei were selected in each core for counting. In
each case, signals for probe and control were counted in 40–60
cells. Amplification of KRAS was defined as a final ratio obtained
for KRAS/CEP12q probes X2.0; KRAS gain was defined as KRAS/
CEP12q ratio41.0 but o2.0. Micrographs were taken from each
amplified spot, using the Zeiss Axiovision software. Copy-number
alterations assessed by SNP array were available for a subset of
74 patients from previous studies, and these data were applied
for analysis of KRAS copy-number alterations in relation to mRNA
expression levels in microarrays.
Oligonucelotide DNA microarray
The RNA was extracted using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) and hybridised to Agilent Whole Human
Genome Microarrays 44 k (Cat. no. G4112F) according to the
manufacturers instruction (www.agilent.com), and as previously
described (Krakstad et al, 2012). Microarray data have been
deposited in the ArrayExpress Archive database, http://www.ebi.
ac.uk/arrayexpress/ (ArrayExpress accession: E-MTAB-1007).
mRNA expression data of KRAS were obtained from DNA-
microarrays and a significance analysis of microarray (SAM) was
performed to investigate genes significantly differentially
expressed (FDR o0.05) in KRAS amplified compared with non-
KRAS-amplified tumours based on SNP-array data. The subset of
patients harbouring KRAS amplifications in FISH analyses with
available microarray data was to small to allow meaningful
statistical analysis (n¼ 3).
PCR and DNA sequencing
Genomic DNA was extracted from freshly frozen tissue samples
and investigated for point mutations in exon 2 codon 12 and 13 of
KRAS and exon 9 and 20 of phosphatidylinositol-4,5-bisphosphate
3-kinase PIK3CA, primers and conditions listed in Supplementary
Section 1. cDNA was synthesised from 1mg RNA by the High capacity
RNA to cDNA kit (Applied Biosystems, Foster City, CA, USA). Gene
expression of KRAS was determined using the TaqMan gene expres-
sion assay KRAS-Hs00932330_m1 (Applied Biosystems). All samples
were run on micro fluidic cards with GAPDH-Hs99999905_m1 as
endogenous control according to manufacturers instruction, and
as previously described (Krakstad et al, 2012).
Statistical analysis
Statistics were performed using the statistical programme SPSS 18.0
(Quarry Bay, Hong Kong). Associations between categorical variables
were evaluated by Pearson’s w2-test. Mann–Whitney U-test was used
for analysis of continuous variables between categories. P-values
represent two-sided tests and are considered of statistical significance
when Po0.05. Univariate analyses of time to recurrence (recurrence-
free survival) and death because of endometrial carcinoma (disease-
specific survival) were performed using the Kaplan–Meyer method.
Differences in survival were estimated by the Mantel–Cox log-rank
test.
In the statistical analysis, cutoff values were based on quartiles,
also considering the frequency distribution for each marker, the
size of subgroups and number of events in each category. Groups
with similar survival were merged.
RESULTS
Amplification of KRAS is associated with aggressive
disease and metastasis
Analysis of KRAS copy-number changes by FISH analysis showed a
large variation in KRAS/CEP12q gene probe ratio from 2 : 2 to
o20 : 2. Defining cases with a ratioX1 ando2 as gain; andX2 as
amplified in the FISH analysis, KRAS gain or amplification was
detected in 3% (13 of 414) of the primary endometrial carcinomas
investigated (Figure 1A–D). There was no significant difference
between gain and amplification of KRAS gene copy number in
terms of prognosis. Presence of KRAS gain or amplification
were highly significantly associated with traditional markers for
aggressive phenotype including high age, FIGO stage, non-
endometrioid histology, high grade, presence of lymph node
metastasis, aneuploidy and loss of hormone receptors (Table 1).
Gain or amplification of KRAS was also highly significantly
associated with poor prognosis with a 46% 5-year survival
compared with 87% for patients with unamplified status
(Po0.001) (Figure 1B). Amplification of KRAS maintains its
independent prognostic impact in Cox multivariate analysis when
adjusted for age, histological subtype, grade and FIGO stage
(HR¼ 2.6, 95% CI: 1.2–5.8, P¼ 0.02). When adjusting for adjuvant
treatment, in addition to these clinico-pathological variables,
KRAS amplification also maintained its independent prognostic
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Figure 1 Fluorescence in situ hybridisation (FISH) for KRAS copy numbers showing no KRAS amplification with CEP12 (green)/KRAS probe (red) ratio 2:2
(A); KRAS gain with KRAS/CEP12 gene probe ratio 2:3 (B); KRAS amplification with KRAS/CEP12 gene probe ratio 2:4 (C); KRAS polysomy with KRAS/CEP12
ratio 4:6 (D) and impact of copy numbers on disease-specific survival in endometrial carcinoma (E). Survival curves are estimated by the Kaplan–Meier
method with numbers of cases (events) given for cases with amplification/gain compared with unamplified cases. Proportion of cases with KRAS gene
amplification/gain increased significantly from primary (13 of 414) to metastatic (11 of 61) lesions (Po0.001, FE test) (F).
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impact in Cox’ multivariate analyses (HR¼ 2.7, 95% CI: 1.2–6.1,
P¼ 0.014). When comparing primary and metastatic endometrial
carcinoma lesions, we find a significant increase in the proportion
of samples with KRAS gain or amplification from 3% in 414
primary lesions investigated to 18% in 61 metastatic lesions
studied (Po0.001) (Figure 1C). There was no significant correla-
tion between KRAS amplification and PIK3CA mutations (Table 1).
However, KRAS amplification was highly significantly correlated to
pathological p53 expression estimated by immunohistochemistry
(Table 1). In analysis of differentially expressed genes in tumours
harbouring KRAS amplifications (n¼ 10) compared with tumours
without KRAS amplifications (n¼ 64), we find seven genes to be
significantly differentially expressed. Two genes were upregulated,
whereas five genes were downregulated as listed in Table 4.
High KRAS mRNA level reflects aggressive phenotype
To further investigate the effect of KRAS amplification on mRNA
levels, we used mRNA microarrays from 122 primary and 19
metastatic lesions, and a validation cohort analysing mRNA
expression of KRAS by qPCR in additionally 161 freshly frozen
primary endometrial carcinoma lesions. High KRAS mRNA
expression was significantly associated with high FIGO stage,
non-endometrioid histology, high grade, lymph node metastasis,
aneuploidy and hormone receptor loss (Table 2, Figure 2A and B).
The KRAS mRNA levels increased significantly from primary to
metastatic lesions (Figure 2C) and in amplified compared to
unamplified samples (estimated by SNP array, Figure 2D). In line
with this, high KRAS mRNA level was associated with poor
Table 1 Clinico-pathological variables related to KRAS gene amplification
analysed by FISH for 414 patients
Variable
Amplified,
n (%)
Not
amplified,
n (%) P-valuea
Age
p66 3 (1.3) 235 (98.7) 0.01
466 10 (5.7) 166 (94.3)
BMIb
p25 3 (2.2) 135 (97.8) 0.2
425 10 (4.5) 212 (95.5)
FIGO stagec
I–II 7 (2.0) 341 (98) 0.009
III–IV 6 (9.1) 60 (90.9)
Histological typed
Endometroid 6 (1.8) 335 (98.2) 0.003
Non-
endometroid
7 (9.6) 66 (90.4)
Gradee
Low-medium 3 (1.1) 281 (98.9) 0.002
High 10 (7.9) 117 (92.1)
Lymph nodef
Negative 5 (1.7) 298 (98.3) 0.001
Postitive 5 (13.5) 32 (86.5)
Ploidyg
Diploid 4 (1.7) 231 (98.3) 0.006
Aneuploid 5 (9.6) 47 (90.4)
ERah
Positive 5 (1.6) 306 (98.4) 0.003
Negative 8 (8.4) 87 (91.6)
PRi
Positive 3 (1) 301 (99) o0.001
Negative 9 (8.6) 96 (91.4)
PIK3CA mutj
N.m.d 7 (3.8) 177 (96.2) 0.33
Mutated 0 (0) 31 (100)
P53k
High 9 (100) 0 (0) o0.001
Low 71 (21.9) 253 (78.1)
Abbreviations: BMI¼ body mass index; ER¼ oestrogen receptor; FIGO¼ International
Federation of Gynaecology and Obstetrics; FISH¼ fluorescence in situ hybridisation;
KRAS¼Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue;
N.m.d¼ no mutations detected; PR¼ progesterone receptor. Data missing: b54, d8,
e3, f74, g127, h4, i7, j199, k81. aFisher’s exact test. cFIGO 2009 Criteria.
Table 2 Clinico-pathological variables related to KRAS gene expression
analysed by qPCR for 161 patients
Variable
High
expression,
n (%)
Low
expression,
n (%) P-value
Age
p66 20 (21.5) 74 (78.5) 0.2
466 21 (31.3) 46 (68.7)
BMIa
p25 14 (25.5) 41 (74.5) 0.7
425 27 (28.1) 69 (71.9)
FIGO stageb
I–II 28 (21.9) 100 (78.1) 0.04
III–IV 13 (39.4) 20 (60.6)
Histological type
Endometroid 25 (18.9) 107 (81.1) o0.001
Non-
endometroid
16 (55.2) 13 (44.8)
Gradec
Low-medium 17 (16) 89 (84) o0.001
High 24 (44.4) 30 (55.6)
Lymph noded
Negative 28 (22.2) 98 (78.8) 0.02
Positive 10 (52.6) 9 (47.4)
Ploidye
Diploid 19 (19) 80 (81) 0.001
Aneuploid 18 (50) 18 (50)
ERaf
Positive 21 (17) 101 (83) o0.001
Negative 19 (53) 17 (47)
PRg
Positive 20 (16) 104 (84) o0.001
Negative 19 (56) 15 (44)
PIK3CA muth
N.m.d 33 (25.6) 96 (74.4) 0.47
Mutated 6 (28.6) 15 (78.4)
P53i
High 20 (57.1) 15 (42.9) o0.001
Low 17 (16.5) 86 (83.5)
Abbreviations: BMI¼ body mass index; ER¼ oestrogen receptor; FIGO¼ International
Federation of Gynaecology and Obstetrics; KRAS¼Homo sapiens v-Ki-ras2 Kirsten rat
sarcoma viral oncogenes homologue; N.m.d¼ no mutations detected; PR¼ progesterone
receptor. The P-value was based on the w2-test or Fisher’s exact test as indicated.
Data missing: a10, c1, d16, e26, f3, g3, h11, i23. bFIGO 2009 criteria.
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prognosis in the validation cohort (n¼ 161; Figure 2E, P¼ 0.003),
and with a similar trend for the slightly smaller micro-array cohort
(n¼ 122; P¼ 0.08). In Cox multivariate analysis KRAS mRNA
expression did not maintain its prognostic significance (HR¼ 1.32,
95% CI: 0.9–2.0, P¼ 0.17) adjusted for age, histological type, grade
and FIGO stage. Presence of mutations in the PIK3CA gene was not
correlated with increased KRAS mRNA expression (Table 2). High
KRAS mRNA expression was significantly correlated to patholo-
gical p53 expression by immunohistochemistry (Table 2).
Mutations of KRAS
As KRAS mutations have been linked to response to targeted
therapy in other cancer types, and its relation to prognosis in
endometrial cancer is unsettled, we further investigated primary
and metastatic lesions for presence of KRAS mutations in DNA
extracted from freshly frozen 264 primary- and 22 metastatic
lesions. We found that 14.7% of primary tumours harboured
mutations in exon 2 of the KRAS gene. Mutations of KRAS were
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Figure 2 Box-plots showing KRAS mRNA expression levels in relation to
histological grade (A), endometrioid (E) and non-endometrioid (NE)
histological subtypes (B), primary tumours (PT) vs metastatic lesions (ML)
(C) and KRAS amplified vs unamplified status (SNP array (Salvesen et al,
2009)) (D). Estimated disease-specific survival according to expression
levels of KRAS mRNA (qPCR) according to upper quartile with number of
cases (events) given for each category.
Table 3 Clinico-pathological variables correlated to status for KRAS
mutation for 264 patients (Sanger sequencing)
Variable
KRASmutated,
n (%)
KRAS wt,
n (%) P-valuea
Age
p66 23 (16.1) 120 (83.9) 0.3
466 16 (13.2) 105 (86.8)
BMIb
p25 8 (9.8) 74 (90.2) 0.02
425 29 (20.7) 111 (79.3)
FIGO stagec
I–II 30 (13.6) 185 (86.4) 0.4
III–IV 9 (18.4) 40 (81.6)
Histological type
Endometroid 37 (17.1) 179 (82.9) 0.01
Non-
endometroid
2 (4.2) 46 (95.8)
Graded
Low-medium 31 (18.5) 137 (81.9) 0.003
High 8 (7.5) 86 (92.5)
Lymph nodee
Negative 27 (14.4) 161 (85.6) 0.45
Positive 6 (21.4) 22 (78.6)
Ploidyf
Diploid 25 (14.8) 144 (85.2) 0.5
Aneuploid 7 (13.5) 45 (86.5)
ERag
Positive 28 (15.5) 153 (84.5) 0.4
Negative 10 (17.5) 47 (82.5)
PRh
Positive 30 (16.9) 148 (83.1) 0.3
Negative 8 (15.8) 55 (87.3)
PIK3CA muti
N.m.d 31 (14.6) 181 (85.4) 0.2
Mutated 3 (8.3) 33 (91.7)
P53j
High 7 (12.7) 48 (87.3) 0.3
Low 26 (17.3) 124 (82.7)
Abbreviations: BMI¼ body mass index; ER¼ oestrogen receptor; FIGO¼
International Federation of Gynaecology and Obstetrics; KRAS¼Homo sapiens
v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue; N.m.d¼ no mutations
detected; PR¼ progesterone receptor. Data missing: c42, d2, e48, f25, g26, h23, i16,
j59. aw2-test. bFIGO 2009 criteria.
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significantly more often present in grade 1 and 2 tumours, the
endometrioid subtype and among obese patients, but no other
significant associations were seen between mutational status for
KRAS and any of the other variables investigated (Table 3). In line
with this, KRAS mutations did not influence prognosis (P¼ 0.67)
(Figure 3A). When comparing primary to metastatic endometrial
carcinoma lesions, we find no increase in the proportion of
samples with KRAS mutations. Contrasting the findings for KRAS
amplifications, patients with KRAS mutations have lower KRAS
mRNA expression than patients without KRASmutations in exon 2
(P¼ 0.035) (Figure 3B). Although not significantly anti-correlated,
only one of the 39 KRAS-mutated samples was KRAS amplified.
Interestingly, we find that only 3 of 36 patients harbouring PIK3CA
mutations had overlapping KRAS mutations (Table 3). Mutation of
KRAS was not correlated to p53 expression.
DISCUSSION
Alterations of KRAS are considered to be an important biological
factor in several cancer types (Pylayeva-Gupta et al, 2011). Over
the last decade, the main focus has been on KRAS mutation as a
predictive marker for response to EGFR inhibition (Pao et al, 2005;
Lievre et al, 2006). In colorectal- and non-small-cell lung cancers,
KRAS mutations have been reported to be associated with poor
prognosis (Rosell et al, 1993; Span et al, 1996; Fukuyama et al,
1997). Mutation of KRAS has also been linked to polypoid growth
in colorectal cancer (Chiang et al, 1998).
In endometrial cancer, it is mainly KRAS mutations that
previously have been studied in relation to clinical phenotype
(Mizuuchi et al, 1992; Ito et al, 1996; Esteller et al, 1997; Jones et al,
1997; Semczuk et al, 1998). Several studies have shown that KRAS
mutations may be present in endometrial hyperplasia’s with
atypia, presumed to be precursor lesions, suggesting mutations as
an early event in the endometrial carcinogenesis (Mutter et al,
1999). The prognostic importance of KRAS mutational status in
endometrial carcinomas has been inconsistent. Two studies
reported a 14% mutation rate with no prognostic impact
(Esteller et al, 1997; Semczuk et al, 1998), apparently in line with
our data. In contrast, Ito et al (1996) showed that 18% of 221
studied endometrial cancer patients had KRAS mutations asso-
ciated with lymph-node metastasis and poor survival among
patients above 60 years of age (Ito et al, 1996). Their reported
mutation rate is in line with our findings, but our higher frequency
amongst endometrioid grade 1 and 2 tumours, and the same
frequency of mutations detected in primary and metastatic lesions
in the present study is in contrast to their findings but more in line
with earlier studies linking KRAS mutations to early steps in
endometrial carcinogenesis (Pappa et al, 2006).
Interestingly, in the present and to date most comprehensive
study of KRAS alterations in primary and metastatic lesions from
endometrial carcinoma patients, we find that high KRAS mRNA
expression and KRAS amplification, in contrast to KRAS mutation,
are associated with a large range of surrogate markers for
unfavourable outcome and poor disease-specific survival. Appar-
ently in line with this, we find a trend towards lower KRAS mRNA
expression among KRAS-mutated cases, while samples with KRAS
amplifications have significantly higher levels of KRAS mRNA
expression and aggressive phenotype. Also the fact that mRNA
expression levels and KRAS amplification increased significantly
from primary- to metastatic lesions suggests an importance of
theses alterations later in the carcinogenic process compared with
KRAS mutations.
Of the differentially expressed genes in patients harbouring
KRAS amplifications it is interesting that upregulation of Ets2 has
been associated with poor prognosis in both pancreatic and breast
cancer (Zhang et al, 2011; McBryan et al, 2012), and down-
regulation of SOX11 have been associated with poor prognosis in
ovarian cancer (Sernbo et al, 2011). However, more research needs
to be done to elucidate KRAS-dependent gene expression
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Figure 3 Estimated disease-specific survival according to KRAS mutation status in endometrial carcinoma primary tumours with numbers of cases (events)
for each category (A). Box-plots showing KRAS mRNA expression levels by qPCR in relation to KRAS mutation status (Mann–Whitney U-test) (B).
Table 4 Genes significantly differentially expressed in patients with
amplified KRAS compared with non-amplified patients (FDR p0.05)
Gene name Description
Fold
change
Upregulated 41.5 fold
C6orf117 Chromosome 6 open reading frame 117 3.3
ETS2 V-ets erythroblastosis virus E26 oncogene
homologue 2
2.2
Downregulated 41.5 fold
LMO1 LIM domain only 1  3.8
CRTAC1 Cartilage acidic protein 1  2.5
SOX11 (Sex determining region Y)-box 11  1.8
UGT2A3 UDP glucuronosyltransferase 2 family,
polypeptide A3
 1.6
FABP1 Fatty acid-binding protein 1  1.5
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regulation in endometrial cancer, which eventually could lead to
new KRAS-targeted therapies.
To date, comprehensive genetic profiling of primary lesions
searching for potential targets for new therapeutics, have led to
only a few biomarker restricted clinical trials, of which some with
promising results (Janku et al, 2012). Still, in a setting with
systemic disease, molecular alterations in metastatic lesions may
be even more important, although so far basically unexplored for
KRAS status in endometrial cancers. Our findings support that
KRAS amplification and overexpression are more prevalent in
metastatic compared with primary lesions, and may be of
particular relevance for targeting therapies in a metastatic setting.
Our data clearly suggest that KRAS alterations are linked to
clinical phenotypes in endometrial carcinomas with increase in
copy-number and mRNA expression levels from primary to
metastatic lesions.
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